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Tumorigenic proteins upregulated in the MYCN-amplified
IMR-32 human neuroblastoma cells promote
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Abstract. Childhood neuroblastoma is one of the most
common types of extra-cranial cancer affecting children with
a clinical spectrum ranging from spontaneous regression to
malignant and fatal progression. In order to improve the clinical outcomes of children with high-risk neuroblastoma, it is
crucial to understand the tumorigenic mechanisms that govern
its malignant behaviors. MYCN proto-oncogene, bHLH transcription factor (MYCN) amplification has been implicated in
the malignant, treatment-evasive nature of aggressive, highrisk neuroblastoma. In this study, we used a SILAC approach to
compare the proteomic signatures of MYCN-amplified IMR-32
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and non-MYCN-amplified SK-N-SH human neuroblastoma
cells. Tumorigenic proteins, including fatty-acid binding
protein 5 (FABP5), L1-cell adhesion molecule (L1-CAM), baculoviral IAP repeat containing 5 [BIRC5 (survivin)] and high
mobility group protein A1 (HMGA1) were found to be significantly upregulated in the IMR-32 compared to the SK-N-SH
cells and mapped to highly tumorigenic pathways including,
MYC, MYCN, microtubule associated protein Tau (MAPT),
E2F transcription factor 1 (E2F1), sterol regulatory element
binding transcription factor 1 or 2 (SREBF1/2), hypoxiainducible factor 1α (HIF-1α), Sp1 transcription factor (SP1)
and amyloid precursor protein (APP). The transcriptional
knockdown (KD) of MYCN, HMGA1, FABP5 and L1-CAM
significantly abrogated the proliferation of the IMR-32 cells at
48 h post transfection. The early apoptotic rates were significantly higher in the IMR-32 cells in which FABP5 and MYCN
were knocked down, whereas cellular migration was significantly abrogated with FABP5 and HMGA1 KD compared
to the controls. Of note, L1-CAM, HMGA1 and FABP5 KD
concomitantly downregulated MYCN protein expression and
MYCN KD concomitantly downregulated L1-CAM, HMGA1
and FABP5 protein expression, while survivin protein expression was significantly downregulated by MYCN, HMGA1 and
FABP5 KD. In addition, combined L1-CAM and FABP5 KD
led to the concomitant downregulation of HMGA1 protein
expression. On the whole, our data indicate that this inter-play
between MYCN and the highly tumorigenic proteins which
are upregulated in the malignant IMR-32 cells may be fueling
their aggressive behavior, thereby signifying the importance
of combination, multi-modality targeted therapy to eradicate
this deadly childhood cancer.
Introduction
Neuroblastoma is a malignancy caused by the hyperplasia of
naive neural crest cells (1). It is the most common solid tumor
affecting children <5 years of age, and the third most common
cause of pediatric cancer-related mortality (2), accounting
for 7% of childhood malignancies and 15% of childhood
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cancer‑related mortalities (3). The disease is known for its
broad range of clinical behavior and variable responses to
treatment (4). This clinical heterogeneity is elucidated by the
fact that some neuroblastomas can spontaneously regress or
differentiate into a benign form, ganglioneuroma, while others
are not responsive to current therapies (5). Even though the
prognosis for children with neuroblastoma is generally good,
the survival rates for children with high-risk neuroblastomas
are still poor, despite advanced therapeutic strategies (6).
Several transcription factors have been shown to be
involved in the pathogenesis of neuroblastoma by enhancing
cancer cell proliferation (7). MYCN proto-oncogene, bHLH
transcription factor (MYCN), one of these transcription
factors, is a phosphoprotein in the MYC family of transcription factors, encoded by the MYCN oncogene (7). The
amplification of MYCN is one of the first most important
genetic signatures of neuroblastoma (8). Patients with neuroblastoma carrying a MYCN amplification are classified in
the high-risk group, and their 5-year overall survival rate
following diagnosis does not exceed 50% (9). An amplification leading to the aberrant expression of MYCN has been
associated with tumor aggressiveness, resistance to chemotherapy and the inability to differentiate (10). In fact, MYCN
amplification confers cell resistance to apoptosis induced by
the tumor necrosis factor‑related apoptosis-inducing ligand
system (11), whereas MYCN silencing promotes proliferation
arrest, differentiation and the apoptosis of human neuroblastoma cells (12).
In the present study, we conducted a pilot proteomics
analysis to compare the proteomic signature of the MYCNamplified IMR-32 cells to that of the non-MYCN-amplified
SK-N-SH human neuroblastoma cells using stable isotope
labeling by amino acids in cell culture (SILAC) strategy (13).
Of the differentially expressed proteins (based on expression
value and fold change) between the IMR-32 and SK-N-SH
cells, we were particularly interested in proteins upregulated
in the IMR-32 compared to the SK-N-SH cells that mapped
to upstream regulators [MYCN, MYC, hypoxia-inducible
factor-1α (HIF-1α), E2F transcription factor 1 (E2F1),
Sp1 transcription factor (SP1), KIT ligand (KITLG), interleukin 3 (IL3), amyloid precursor protein (APP), insulin
receptor (INSR) and sterol regulatory element binding transcription factor 1 or 2 (SREBF1/2)] predicted by Ingenuity
Pathway Analysis (IPA; Ingenuity Systems, Inc., Redwood City,
CA, USA; 2000‑2014) to be activated in the IMR-32 cells.
These included: L1 cell adhesion molecule (L1-CAM); high
mobility group protein A1 (HMGA1); fatty acid-binding
protein 5 (FABP5); and baculoviral IAP repeat containing 5
[BIRC5 (survivin)].
In the present study, we aimed to determine the interaction between the above-mentioned molecules and MYCN
in the IMR-32 cells and the effect of transcriptional
knockdown (KD) of these targets on cellular proliferation,
migration and apoptosis. We also wished to determine the
cellular bio-function after single-target versus double-target
transcriptional KD of the said proteins and whether an added
effect would be observed. In addition, we were interested in
examining whether a crosstalk exists between these proteins
as determined by differential protein expression levels of one
target after transcriptional KD of each of the other targets.

Materials and methods
Reagents and human cell lines. The IMR-32 (MYCNamplified) and SK-N-SH (non-MYCN-amplified) cells are
human neuroblastoma/neuroepthelioma cell lines purchased
from the American Type Culture Collection (ATCC, Manassas,
VA, USA) where routine STR testing was conducted and the
cells were confirmed to derive from human species. In addition,
the cells were routinely tested for mycoplasma, aerobic and
anaerobic bacteria, and human pathogenic viruses including
human immunodeficiency virus (HIV), hepatitis B (HepB),
human papilloma virus (HPV), Epstein-Barr virus (EBV)
and cytomegalovirus (CMV), all of which our cells tested
negative for and were used within 6 months of purchase from
ATCC. The cells were cultured in minimal essential Eagle's
medium (EMEM; cat. no. M2279) supplemented with 2 mM
L-glutamine (cat. no. 7513; Sigma, St. Louis, MO, USA),
2% penicillin streptomycin (cat. no. P4333SIGMA), 1 mM
sodium pyruvate (cat. no. S8636), 2% non-essential amino acids
(cat. no. M7145) and 10% fetal bovine serum (cat. no. F9665)
(all from Sigma). The cells were cultured to 80% confluence in
T25 flasks at 5% CO2 and 37˚C. The medium was replenished
every 48 h. After 8 days, the cells covering 80% of the flask
were collected and transferred into a 15 ml falcon tube to be
centrifuged at 200 x g for 10 min at 4˚C. The old medium
was discarded and the cells were re-suspended in 10 ml of
fresh medium and transferred into a T75 flask. The cells
harvested from T75 flasks were frozen in Corning® Cryotubes
(Corning Inc., New York, NY, USA) using 50% fetal bovine
serum (FBS), 40% EMEM and 10% DMSO (D2650; Sigma)
to a final volume of 1 ml. The cryotubes were frozen first at
-80˚C for 24 h in isopropanol to provide a gradual decrease in
temperature. They were then transferred to liquid nitrogen for
long term storage.
SILAC proteomics sample preparation. The IMR-32 and
SK-N-SH neuroblastoma cells were grown in the standard
culture conditions until they reached confluency after which
they were washed 6 times with serum-free medium and then
cultured in serum-free medium supplemented with ‘heavy’
isotopes where arginine and lysine were replaced with 13C6-Arg
and 13C6, 15N2-Lys (Cambridge Isotopes, Andover, MA, USA) for
6 doublings to ensure incorporation of the isotopes into the entire
cellular population. After 6 doublings, the cells were collected,
lysed, quantified and mixed together into one SuperSILAC
mastermix cocktail and saved at -80˚C. The cells were then
cultured in serum-free growth medium supplemented with
‘light’ isotopes where arginine and lysine were replaced with
12
C6-Arg and 12C6, 14N2-Lys until they reached ~80% confluency.
The cells were lysed at that point and quantified, and a
‘spike‑in’ strategy used to spike-in the ‘heavy’ labeled cellular
lysates into the ‘light’ labeled cellular lysates at a 1:1 ratio.
Approximately 100 µg of total protein mixture (50:50 µg of
cell lysate:SuperSILAC cocktail) was loaded onto a 4-12%
polyacrylamide gel and electrophoresed until the proteins were
well-separated. The gel was fixed and stained with Commassie
Blue (Bio-Rad, Hercules, CA, USA) then de-stained overnight in
H2O at 4˚C. The gels were then sliced into ~35-40 bands which
underwent in-gel digestion with trypsin (Promega, Madison,
WI, USA) using a previously documented protocol (14) and
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the resultant peptides derived from each band were dried by
vacuum centrifugation (240 x g) at room temperature, and
re-suspended in 6 µl of 0.1% TFA for analysis by mass spectrometry and proteomics analysis as previously described (15).
Mass spectrometry analysis and protein identification and
quantification. The methods used to conduct the mass spectrometry and protein identification and quantification were
exactly as described in the study by Formolo et al (15).
IPA, STRING protein networks and Enrichr analysis tool.
Ingenuity Systems, Inc. 2000-2014 (content version, 18030641;
release date, December 6, 2013) was used to derive the target
molecules within the data set, upstream regulators, molecule
type, predicted activation status with activation z-score and
P-values of the proteins differentially expressed between the
IMR-32 and SK-N-SH cells based on expression of and number
of peptides detected per protein, where anything >2-fold
is considered upregulated and anything below 0.5-fold is
considered downregulated. The Enrichr (16,17) tool was used
to annotate the differentially expressed proteins between the
IMR-32 and SK-N-SH cells. Proteins in the network that were
differentially expressed in the IMR-32 cells were mapped to
the top diseases and bio-functions. Differential expression was
determined as either upregulated (>2-fold) or downregulated
(<0.5-fold) in the IMR-32 compared to the SK-N-SH cells.
The STRING protein network tool was used to determine any
interactions (experimentally determined, from curated databases and text-mining) between our proteins of interest.
Protein extraction for validation by western blot analysis.
The IMR32 and SK-N-SH cells were collected into 15-ml
falcon tubes and centrifuged at 200 x g for 10 min at 4˚C. The
medium was discarded and the pellet was washed twice with
Dulbecco's phosphate-buffered saline (PBS; D8537; Sigma).
PBS was then discarded and the cells were incubated on ice
for 40 min with 120 µl of lysis buffer (for a confluent T75 flaks)
composed of 50 Mm tris-HCl (pH 7.5), 1 mM EDTA, 250 mM
NaCl, 50 mM NaF, 0.1 mM Na 3VO 4, 0.5% Titron X-100
and 1X protease inhibitor cocktail (cat no. 11697498001;
Roche, Indianapolis, IN, USA). The lysates were transferred
to Eppendorf tubes where they were centrifuged at 4˚C for
20 min at 8,000 x g to eliminate cellular debris. The supernatants were then transferred to new Eppendorf tubes where
they were mixed with 60 µl of the 3X sample buffer (0.5 M
tris-HCl, glycerol, 10% SDS, β-mercaptoethanol and 0.05%
bromophenol blue) in preparation for western blot analysis.
Western blot analysis. Protein expression was confirmed by
western blot analysis as previously described (18). Briefly,
For L1-CAM, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and HMGA1 detection, a 10% polyacrylamide
(cat. no. 161-0156; Bio-Rad) gel was used; however, for FABP5
and MYCN detection a 12% polyacrylamide gel was used. A
5% stacking gel was used to form the wells. The extracted
proteins were separated on gels using a current of 150 mV.
Proteins were then transferred to a PVDF membrane (cat.
no. 1620177; Bio-Rad) for 90 min at 100 mV which was then
blocked using 5% BSA (cat. no. A2153-100G; Sigma) diluted
in 1X TBS with 1% Tween-20 (cat. no. 9005-64-5).
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The blots were incubated with rabbit monoclonal L1-CAM
(cat. no. ab20148), HMGA1 (cat. no. ab129153), FABP5 (cat.
no. ab84028), survivin (cat. no. ab469) (all from Abcam,
Cambridge MA, USA) and MYCN antibodies (cat. no. 9405;
Cell Signaling Technology, Danvers, MA, USA) and with
mouse monoclonal GAPDH antibody (cat. no. ab9484)
(Abcam) overnight (all diluted 1:1,000 in TBS-T +5% BSA
blocking solution). The blots were washed 5 times for 5 min
with TBST and then incubated with secondary antibodies
[goat anti-rabbit (cat. no. 170-5046) or goat anti-mouse (cat.
no. 170-5047) HRP-conjugated secondary antibodies from
Bio-Rad] for 1 h. After washing, the blots were incubated with
Clarity Western ECL substrate (cat. no. 1705060; Bio-Rad) for
3 min and imaged using the Bio-Rad© ChemiDoc system and
analyzed using ImageLab® software. The bands obtained were
normalized to GAPDH.
Transcriptional KD of target proteins. The 4 siRNA oligonucleotides for L1-CAM (Hs L1-CAM_4 SI00009296, Hs
L1-CAM_3 SI00009289, Hs L1-CAM_2 SI00009282 and Hs
L1-CAM_1 SI00009275; Qiagen, Valencia, CA, USA), HMGA1
(D-004597-01 HMGA1, D-004597-02 HMGA1, D-004597-03
HMGA1 and D-004597-18 HMGA1; Dharmacon, Lafayette,
CO, USA), MYCN (Hs_MYCN_7 SI03113670, Hs_MYCN_6
SI03087518, Hs_MYCN_5 SI03078222 and Hs_MYCN_3
SI00076300; Qiagen) and FABP5 (Hs_FABP5_10 SI04277553,
Hs_FABP5_9 SI04210948, Hs_FABP5_8 SI04210941 and
Hs_FABP5_5 SI03145835; Qiagen) were reconstituted in
RNAase-free water to a final concentration of 10 µM. A total
of 5x105 cells were seeded in each well of a 6-well plate in a
final volume of 2 ml of antibiotics-free medium. The cells were
transfected with the siRNA using the fast-forward Hiperfect
transfection protocol following the manufacturer's instructions
(cat. no. 301705; Qiagen). A final concentration of 100 nM of
each siRNA was achieved by mixing 10 µl of the 10 µM siRNA
with 10 µl of Hiperfect (cat. no. 301705; Qiagen) and 370 µl of
OptiMEM (cat. no. 31985-062; Life Technologies, Carlsbad,
CA, USA). The mixture was incubated at room temperature for
20 min, and added in a drop-wise manner to the corresponding
wells. The negative control was prepared by treating the cells
with 90 µl of OptiMEM and 10 µl of Hiperfect. The cells were
then incubated with the siRNAs for 48 h, lysed and processed
for western blot analysis.
WST-1 cell proliferation assay. In order to examine the effects
of KD on cellular proliferation, a WST-1 cell proliferation assay
was conducted. A total of 5x104 cells were cultured in each
well of a 96-well plate in a final volume of 100 µl. Duplicates
of each condition were prepared. The cells were transfected
with L1-CAM, HMGA1, MYCN, FABP5 or scrambled siRNAs
in a final concentration of 100 nM. The cells were incubated
in 100 µl growth medium for 24, 48 and 72 h and treated with
10 µl of WST-1 reagent (cat. no. ab155902; Abcam) per well
prior to reading. The absorbance was detected after 3 h using
an Epoch™ Microplate Spectrophotometer at 450 nm (BioTek,
Winooski, VT, USA).
Annexin V-FITC/propidium iodide (PI) apoptosis detection assay. The IMR32 cells were cultured in a 6-well plate
(5x105 cells/well), and transfected with the various siRNA
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constructs as described above. Negative control cells were
either unlabeled/untreated or Annexin V-FITC- and PI-labeled
and untreated. Positive control cells were transfected
with 100 nM siRNA of our target constructs and labeled
with Annexin V-FITC and PI or Annexin V-FITC alone.
The cells were then collected at 48 h using accutase (cat.
no. A11105‑01; Thermo Fisher Scientific, Waltham, MA, USA)
and centrifuged at 200 x g for 5 min at 4˚C. They were then
re-suspended in 500 µl of 1X binding buffer, treated with 5 µl
of Annexin V-FITC or PI from Abcam (cat. no. ab14085) and
incubated in the dark for 5 min prior to flow cytometric analysis
using FACSCalibur flow cytometer (BD Biosciences, San Jose,
CA, USA). Data were analyzed using IQuest Pro software
(version 5.1) (BD Biosciences). IMR32 cells were identified
by their forward-scatter (FSC) and side-scatter (SSC) characteristics. Viable, early apoptotic, late apoptotic and dead cell
populations were identified as Annexin V-/PI-, Annexin V+/PI-,
Annexin V+/PI+ and Annexin V-/PI+, respectively. Cells stained
with Annexin V-FITC or PI alone were used to adjust color
compensation settings on flow cytometer. A minimum of
20,000 cell events were recorded for each sample.
Wound healing migration assay. The IMR-32 cells were grown
to ~70% confluency in triplicates of 12-well plates in standard
culture medium and conditions. FABP5 or HMGA1 siRNA
transfection was conducted as described above and after 24 h,
the cells were scraped down the midline of the plate to resemble
a ‘wound’. The cells which were scraped off were washed 2X
with serum-free medium and fresh medium replenished and
the cells were then imaged (0 h time-point) and cultured under
standard growth culture conditions for 24 h. The cells were
then imaged at several random fields down the scratched
‘wound’ area and the area (µM2) of ‘wound-closure’ after 24 h
in siRNA KD-compared to control siRNA-transfected cells
was measured using AxioVision Systems software (Zeiss,
Oberkochen, Germany). The average of the areas of multiple
random fields was represented as a fold change compared to
untransfected controls and graphed using Microsoft Excel
software.
Statistical analysis. Experiments were conducted in triplicate,
repeated 3 independent times and the means ± the standard
error of the means (SEM) of all 3 experiments was calculated
and plotted. A two-sided Student's t-test was used to determine statistically significant differences between groups. A
one-way analysis of variance (ANOVA) test was used followed
by a post hoc Fisher's least significant difference (LSD) test
to determine the significance among the means of multiple
groups obtained from ≥3 independent experiments. The
means ± SEM of 3 or more experiments was derived and
graphed using Microsoft Excel software. Statistical significance was set at a P-value <0.05.
Results
Top networks, diseases and bio-functions to which overexpressed proteins in IMR-32 cells are mapped. We conducted
preliminary proteomics analysis of the MYCN-amplified
IMR-32 compared to the non-MYCN-amplified SK-N-SH
human neuroblastoma cell lines using a highly quantitative

SILAC methodology. The significant, differentially expressed
proteins were then annotated using IPA in order to predict
the upstream regulators of highly tumorigenic proteins in the
IMR-32 compared to the SK-N-SH cells. The total numbers of
differentially expressed proteins were found to be 875 out of
4,960 proteins (either >2-fold upregulated or <0.5-fold downregulated) in the IMR-32 compared to the SK-N-SH cells.
These proteins were affiliated with upstream regulators that
IPA predicted to be activated in the IMR-32 compared to the
SK-N-SH cells based on the molecules identified in our dataset
(data not shown).
Table I lists the top diseases and disorders, molecular
and cellular bio-functions, as well as physiological system
development and function categories that proteins significantly overexpressed in the IMR-32 cells are mapped to; the
fold change cut-off was set at ≥2-fold. Renal and urological,
neurological, hereditary and infectious diseases, as well as
organismal injury and abnormalities, were among the top
disease categories that the proteins were mapped to Table IA.
RNA post-transcriptional modification, molecular transport,
RNA trafficking, cellular compromise and gene expression
were among the top molecular and cellular functions that
the overexpressed proteins in the IMR-32 cells were mapped
to Table IB. The physiological system development and
function categories that proteins belonged to included tissue
development, nervous system development and function,
connective tissue development and function and embryonic
development (Table IC).
Fold change and predicted activated up-stream regulators
of proteins overexpressed in IMR-32 compared to SK-N-SH
cells. IPA was used to predict the activation status of the
upstream regulators of the differentially expressed proteins
between the IMR-32 and SK-N-SH cells. Table II lists the top
molecules and the fold change of upregulated proteins which
included, CaM kinase like vesicle associated (CAMKV), tumor
protein D52 (TPD52), argininosuccinate synthetase 1 (ASS1),
FABP6, L1-CAM, FABP5, DNA polymerase γ, catalytic subunit
(POLG), collapsin response mediator protein 1 (CRMP1), ribonuclease H2 subunit B (RNASEH2B) and G protein subunit αO1
(GNAO1). MYCN, hepatocyte nuclear factor 4α (HNF4A),
microtubule associated protein Tau (MAPT), APP and E2F
were predicted to be activated upstream regulators of the
proteins in this dataset, as determined by IPA (based on the
target molecules that were found to be >2-fold upregulated in
the IMR-32 compared to the SK-N-SH cells). In addition to
the top upstream regulators, Table III lists additional upstream
regulators predicted to be activated or inhibited in the IMR-32
compared to the SK-N-SH cells. Of note, is the activation of
cancer-promoting, angiogenic and cancer stemness players, such
as MYC, HIF-1α, eukaryotic translation initiation factor 4γ1
(EIF4G1), IL3, angiopoietin 2 (ANGPT2) and SREBF in the
IMR-32 cells. Molecules predicted to be inhibited in the IMR-32
compared to the SK-N-SH cells included Aly/REF export factor
(ALYREF), Ankyrin (ANK)2, autophagy related 7 (ATG7),
coiled-coil domain containing 88A (CCDC88A), chromatin
target of PRMT1 (CHTOP), cleavage and polyadenylation
specific factor 1 (CPSF1), CPSF2 and CPSF3 among others,
primarily involved in RNA post-transcriptional modification,
molecular transport and RNA trafficking.
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Table I. Functional annotation of proteins upregulated in the IMR-32 compared to the SK-N-SH human neuroblastoma cell lines.
A, Diseases and disorders
Name
Infectious disease
Organismal injury and abnormalities
Renal and urological disease
Hereditary disorder
Neurological disease

P-value

No. of molecules

2.02E-09-1.69E-02
2.02E-09-1.89E-02
4.93E-09-1.69E-02
8.90e-07-1.89e-02
8.90E-07-1.75E-02

135
164
70
41
98

P-value

No. of molecules

2.54E-33-1.73E-02
4.20E-11-1.73E-02
4.20E-11-1.97E-02
1.45E-10-1.90E-02
1.19E-07-1.07E-02

75
75
23
38
180

B, Molecular and cellular functions
Name
RNA post-transcriptional modification
Molecular transport
RNA trafficking
Cellular compromise
Gene expression
Associated network function

Score

RNA post-transcriptional modification, molecular transport,
RNA trafficking
Gene expression, RNA damage and repair, RNA
post-translational modification
Cellular assembly and organization, cellular function and
maintenance, tissue development
Cellular movement, developmental disorder, hereditary disorder
Cellular compromise, cell cycle, cellular assembly and organization

45
45
40
38
38

C, Physiological system development and function
Name
Tissue development
Nervous system development and function
Connective tissue development and function
Embryonic development

Proteins overexpressed in the IMR-32 cells belong to
tumorigenic pathways. The proteins overexpressed in the
IMR-32 compared to the SK-N-SH cells that belonged to
the upstream regulators predicted to be activated by IPA
(SREBF1, SP1, SCAP, SREBF2, IL3, KITLG, FLI1, INSR,
HIF-1α, MYC, EIF4E and ANGPT2 among others), mapped
to signaling pathways that drive cancer stem cell maintenance and propagation (Notch) (19), invasion and metastasis
[Rac1/Pak1/p38/MMP-2 (20) and the leptin signaling
pathway (21)], cancer malignancy [SREBP signaling (22) and
the AGE/RAGE pathway (23)] and proliferation [AMPK pathways (24)]. Table IV lists the upstream regulators predicted to
be activated by IPA, with adjusted P-values for the overexpression level in the IMR-32 cells and the pathways in which these
regulators have been demonstrated to play pivotal roles.

P-value

No. of molecules

8.61E-06-1.57E-02
6.52E-05-1.73E-02
7.68E-04-1.89E-02
7.68E-04-1.73E-02

70
75
55
66

IMR-32 cells significantly overexpress the tumorigenic
proteins, HMGA1, L1-CAM, FABP5 and BIRC5. Of the
highly tumorigenic proteins identified to be upregulated in the
IMR-32 compared to the SK-N-SH cells, we decided to focus
our investigation on L1-CAM, HMGA1, FABP5, BIRC5 and
MYCN as they mapped to several of the activated upstream
regulators, as predicted by IPA and due to their tumorigenic
roles played in various types of cancer as elaborated below in
the ‘Discussion’. Western blot analysis was used to determine
the levels of HMGA1, FABP5, BIRC5 and L1-CAM, as well as
MYCN protein expression between the IMR-32 and SK-N-SH
cells. As expected, we found all these targets to be significantly overexpressed in the IMR-32 compared to the SK-N-SH
neuroblastoma cells. Fig. 1A is a representative demonstration of multiple western blotting experiments verifying the
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Figure 1. Verification of proteomics data. (A) Representative western blot images of L1-cell adhesion molecule (L1-CAM), MYCN proto-oncogene, bHLH
transcription factor (MYCN), high mobility group protein A1 (HMGA1), survivin and fatty-acid binding protein 5 (FABP5) protein expression in the IMR-32
compared to the SK-N-SH cells. (B) Densitometric analysis verified the proteomics data and revealed the significant overexpression of L1-CAM, MYCN,
HMGA1, survivin and FABP5 in the IMR-32 compared to the SK-N-SH cells. Experiments were run in triplicate and repeated >3 times. Results represent the
means ± SEM; *P<0.05 and **P<0.01.

Table II. Fold change of top 10 proteins upregulated in the
IMR-32 versus the SK-N-SH human neuroblastoma cells.
Molecules

Fold change
103.800
39.976
24.995
18.000
16.726
16.708
15.295
15.268
15.250
14.943

CAMKV
TPD52
ASS1
FABP5
POLG
L1-CAM
CRMP1
FABP6
RNASEH2B
GNAO1
Upstream
regulator
MYC
HNF4A
MAPT
APP
E2F

P-value of
overlap predicted

Activation
state

1.52E-18
2.15E-15
7.36E-12
1.10E-11
1.37E-11

Activated

upregulation of these targets, as indicated by the SILAC
proteomics data. Densitometric analysis revealed a significant
upregulation of the protein expression of L1-CAM (~1-fold
overexpressed), MYCN (~7-fold overexpressed), HMGA1

(~0.5-fold overexpressed), BIRC5 (~1-fold overexpressed) and
FABP5 (~4-fold overexpressed) in the IMR-32 compared to
the SK-N-SH cells (Fig. 1B).
Upregulated proteins in IMR-32 cells mapped to the highly
tumorigenic MYCN pathway. The STRING protein network
database was used to analyze the interactions (experimentally determined and from curated databases) between the
activated upstream regulators of the overexpressed proteins
in the IMR-32 cells (HMGA1, L1-CAM, BIRC5, FABP5,
MYC, INSR, SP1, HIF1A and SREBF1/2 among others) and
MYCN (Fig. 2A). In addition, we used STRING protein
network analysis to focus on the interactions between the activated upstream regulators, which our validated proteins (by
western blot analysis; HMGA1, L1-CAM, FABP5 and BIRC5)
mapped to Fig. 2B). Of particular interest, are the various
hubs (proteins with multiple edges) identified, including INSR,
SP1, HIF-1α, MYC, MYCN, HMGA1 and SREBF that show
strong interactions (experimentally-determined, from curated
databases and text-mining) with many other tumorigenic
proteins (Fig. 2A). We further highlight the important interactions (experimentally determined, from curated databases
and text-mining) between our validated targets (by western
blot analysis; HMGA1, BIRC5 and MYCN) and the activated
upstream regulators, SP1, SREBF1, MYC, KITLG, IL3, INSR
and HIF-1α (Fig. 2B). KEGG pathway analysis mapped the
number of molecules to various pathways, most of which are
known tumorigenic drivers, including PI3K/Akt, Ras, Rap1,
Wnt, HIF-1α, transforming growth factor- β (TGF- β ) and
mammalian target of rapamycin (mTOR) and insulin signaling
pathways (Table V). This intricate network of interplay
between these highly tumorigenic proteins warrants further
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Table III. Upstream regulators predicted to be either activated (in addition to the above top 5 upstream regulators), or inhibited
in the IMR-32 compared to the SK-N-SH cells based on the statistically significant over- or underexpression of molecules within
the IPA-derived dataset.
Predicted to be activated

Predicted to be inhibited

MYC, ESRRA, MYCN, INSR, HIST1H1T, HIST1H1A, HIF1A, EIF4E, EIF4G1, SREBF2,
ANGPT2, FLI1, IL3, SREBF1, SCAP, RUVBL1, SP1, CD40LG, EPAS1, KITLG, ADORA2A,
PGR, KAT5, PSEN1
ALYREF, ANK2, ATG7, CCDC88A, CHTOP, CPSF1, CPSF2, CPSF3, CSTF1, DDX39A,
DDX39B, DENR

Table IV. Functional annotation of upstream regulators of the overexpressed proteins in the IMR-32 cells and the signaling
pathways they are affiliate witha.
Pathways

Adjusted
P-value

Genes overexpressed

SREBP signaling_WP1982
Adipogenesis_WP236
Hematopoietic stem cell differentiation
AGE/RAGE pathway_WP2324
SREBF and miR-33 in cholesterol and lipid homeostasis_WP2011
Mitochondrial gene expression_WP391
Nuclear receptors_WP170
Integrated pancreatic cancer pathway_WP2377
Differentiation pathway_WP2848
Translation factors_WP107
Notch signaling pathway_WP61
Rac1/Pak1/p38/MMP-2 pathway_WP3303
AMPK signaling_ WP1403
Leptin signaling pathway_WP2034
Androgen receptor signaling pathway_WP138
DNA damage response (only ATM dependent)_WP710
miR-148/miR-31/FIH1/HIF1? - Notch signaling in glioblastoma_WP3593

8.04E-05
4.00E-04
4.55E-04
9.50E-04
2.79E-03
3.11E-03
9.47E-03
1.20E-02
1.20E-02
1.20E-02
1.67E-02
1.84E-02
1.85E-02
2.08E-02
2.78E-02
4.08E-02
5.00E-02

SREBF1, SP1, SCAP, SREBF2
SREBF1, EPAS1, SP1, HIF1A
IL3, KITLG, FLI1
SP1, INSR, HIF1A
SREBF1, SREBF2
ESRRA, SP1
ESRRA, PGR
IL3, SP1, MYC
IL3, KITLG
EIF4E, EIF4G1
MYC, HIF1A
ANPGPT2, MYC
SREBF1, INSR
SP1, EIF4E
KAT5, SP1
MYC, INSR
HIF1A

As derived from Enrichr using the IPA-predicted activated up-stream regulators dataset.

a

investigation, particularly in pre-clinical, animal models,
whereby multiple targeting of more than one of these players
may yield beneficial, antitumor effects and improve therapeutic outcomes.
Novel pathways link the MYCN-affected proteins in the
IMR-32 cells to cancer malignancy. In addition to the
above‑mentioned pathways, when we combined only MYC,
MYCN and our validated targets in the STRING protein
network analysis (Fig. 3A), we found very strong interactions
between MYC, MYCN, BIRC5 and HMGA1 with Aurora kinase
(AURK)A/B, cyclin-dependent kinase 1 (CDK1), cell division
cycle associated 8 (CDCA8) and INCENP. These players were
mapped to cellular functions highly affiliated with mitosis and
cellular division and proliferation (Table VI). Lastly, L1-CAM
focused network analysis revealed its strong interaction with
neural cell adhesion molecule 1 (NCAM1), neurocan (NCAN),
ezrin (EZR), RDX, ANK1, ANK2, contactin 2 (CNTN2), neuropilin 1 (NRP1), epidermal growth factor receptor (EGFR) and

RAN binding protein 9 (RANBP9) (Fig. 3B), most of which
drive angiogenic and migratory processes to fuel cellular invasion, migration and metastatic spread.
Transcriptional KD experiments reveal interplay between
tumorigenic proteins upregulated in IMR-32 cells. We then
aimed to transcriptionally KD the protein expression of these
molecules and determine the effects of this KD on cellular biofunction. Additionally, we wished to determine whether the
downregulation of one protein would affect the expression level
of the other targets, thereby implicating a potential interplay
between the proteins. Using transient siRNA transfection, we
successfully downregulated the protein expression (Fig. 4A) of
MYCN (~85%), HMGA1 (~60%), FABP5 (~60%) and L1-CAM
(~80%) as determined by western blot analysis at 48 h after
siRNA transfection (Fig. 4B). Of note, L1-CAM, HMGA1 and
FABP5 transcriptional KD led to the significant concomitant
downregulation of MYCN protein expression by ~80, 90 and
75%, respectively (Fig. 5A). In addition, MYCN transcriptional
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Table V. Common tumorigenic pathways that MYCN, BIRC5 and the activated upstream regulators mapped to.
			False
Pathway
Pathway
Observed
discovery
ID no.
description
gene count
rate
4151
5202
4066
5200
4910
4015
4014
4310
4150
5210
4350
4640

PI3K-Akt signaling pathway
Transcriptional misregulation in cancer
HIF-1 signaling pathway
Pathways in cancer
Insulin signaling pathway
Rap1 signaling pathway
Ras signaling pathway
Wnt signaling pathway
mTOR signaling pathway
Colorectal cancer
TGF-β signaling pathway
Hematopoietic cell lineage

6
5
4
5
3
4
3
3
2
2
2
2

1.26E-05
1.26E-05
7.58E-05
5.02E-03
6.48E-03
1.95E-02
2.05E-02
1.84E-02
2.67E-02
2.67E-02
4.08E-02
4.51E-02

Matching proteins in
your network (labels)
ANGPT2, EIF4E, IL3, INSR, KITLG, MYC
FLI1, IL3, MYC, MYCN, SP1
ANGPT2, EIF4E, HIF1A, INSR
BIRC5, HIF1A, KITLG, MYC, EPAS1
EIF4E, INSR, SREBF1
ADORA2A, ANGPT2, INSR, KITLG
ANGPT2, INSR, KITLG
MYC, PSEN1, RUVBL1
EIF4E, HIF1A
BIRC5, MYC
MYC, SP1
IL3, KITLG

When we combined the predicted activated upstream regulators and MYCN in the STRING protein network analysis, the common pathways
identified were highly tumorigenic, including PI3K-Akt, transcriptional misregulation in cancer, pathways in cancer, HIF-1, Wnt, Rap1, Ras,
mTOR, TGF-β and insulin signaling pathways.

Figure 2. Tumorigenic proteins significantly upregulated in the IMR-32 cells mapped to the MYCN proto-oncogene, bHLH transcription factor (MYCN)
pathway. (A) STRING pathway analysis revealed interactions between molecules of activated upstream regulators in IMR-32 cells as predicted by IPA.
Of importance are the various proteins with hubs (multiple edges, red circles), including Sp1 transcription factor (SP1), MYC, MYCN, hypoxia-inducible
factor-1α (HIF-1α), high mobility group protein A1 (HMGA1), INSR, KIT ligand (KITLG), sterol regulatory element binding transcription factor 2 (SREBF2)
and SREBF1. (B) STRING pathway analysis also focused on the strong interactions between the activated upstream regulators which HMGA1, MYCN and
BIRC5 mapped to. Of particular interest are the hubs, including MYCN, MYC, SP1, HIF-1α, SREBF1, BIRC5, HMGA1 and INSR that affiliated with one or
more of our validated targets.

KD led to the significant concomitant downregulation of
L1-CAM, HMGA1 and FABP5 protein expression by ~77, 75
and 70, respectively (Fig. 5B). Moreover, the combined transcriptional KD of L1-CAM and FABP5 led to the significant
concomitant downregulation of HMGA1 protein expression by
~70% (Fig. 5C), while survivin protein expression was abrogated following the transcriptional KD of MYCN, HMGA1
and FABP5 (Fig. 5D). This interplay between these tumorigenic proteins is extremely interesting and warrants further
investigation into the mechanisms utilized by this network to

drive cancerous progression and malignant, treatment-evasive
recurrence in high-risk, MYCN-amplified pediatric neuroblastomas.
Transcriptional KD of tumorigenic proteins inhibits the
proliferation and migration of IMR-32 cells. To determine
the cellular bio-functional effects of the transcriptional
downregulation of our protein targets, we examined the rate
of proliferation of the IMR-32 cells over 5 days following the
transcriptional KD of these tumorigenic proteins. We observed
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Figure 3. Novel pathways link the MYCN proto-oncogene, bHLH transcription factor (MYCN)-affected proteins in IMR-32 cells to cancer malignancy.
(A) STRING pathway analysis revealed very strong interactions between MYCN, BIRC5, high mobility group protein A1 (HMGA1) and the cellular mitosis
and proliferation players AURKA/B, cyclin-dependent kinase 1 (CDK1), CDCA8 and INCENP; (B) whereas L1-cell adhesion molecule (L1‑CAM) showed
very strong interactions with neural cell adhesion molecule 1 (NCAM1), neuropilin-1 (NRP1), NCAN, contactin 2 (CNTN2), RANBP1 and epidermal growth
factor receptor (EGFR) among others most of which are angiogenic markers.

Figure 4. The transcriptional knockdown of tumorigenic proteins significantly decreases protein expression. (A) Transient transfection with siRNA targeting
L1-cell adhesion molecule (L1-CAM), high mobility group protein A1 (HMGA1), MYCN proto-oncogene, bHLH transcription factor (MYCN) and fatty-acid
binding protein 5 (FABP5) abrogated their protein expression. (B) Densitometric analysis of multiple experimental repeats revealed a significant decrease in
the expression of the said proteins compared to control siRNA-transfected cells. Experiments were run in triplicate and repeated >3 times. Results represent
the means ± SEM; *P<0.05 and **P<0.001.
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Figure 5. Transcriptional knockdown experiments reveal an interplay between tumorigenic proteins. (A) Western blot analysis revealed a concomitant significant downregulation of MYCN proto-oncogene, bHLH transcription factor (MYCN) protein expression following the knockdown of L1-cell adhesion
molecule (L1-CAM), high mobility group protein A1 (HMGA1) and fatty-acid binding protein 5 (FABP5) by siRNA in the IMR-32 cells compared to the controls. (B) Conversely, MYCN knockdown by siRNA led to the concomitant significant downregulation of L1-CAM, HMGA1 and FABP5 protein expression,
whereas (C) the combined knockdown of L1-CAM and FABP5 by siRNA led to the concomitant significant downregulation of HMGA1 protein expression.
(D) MYCN, HMGA1 and FABP5 knockdown and the combined dual-target knockdown led to the concomitant downregulation of survivin protein expression.
Non-adjacent bands of western blot experiments were re-aligned side by side to increase the clarity of the presented data and designated by a straight vertical
line. Experiments were run in triplicate and repeated >3 times. Results represent the means ± SEM; *P<0.05 and **P<0.01.

no significant differences in the rate of the proliferation of
IMR-32 cells at 0 and 24 h following the transcriptional KD of
all the above-mentioned siRNA-targeted, tumorigenic proteins
compared to the controls. However, there was a statistically
significant reduction in the rate of cellular proliferation between
the MYCN, L1-CAM, HMGA1 and FABP5 siRNA‑transfected
cells and the controls at 48, 72 and 96 h post-siRNA transfection (Fig. 6A), implicating the role of these proteins in
highly proliferative signaling pathways. The rate of the proliferation of cells targeted with double-target siRNA transfection
(MYCN + L1-CAM, MYCN + HMGA1, MYCN + FABP5,
HMGA1 + L1-CAM, HMGA1 + FABP5 and FAB5 + L1-CAM)
was also significantly decreased from 48 to 96 h post-transfection compared to the controls (Fig. 6B). Double-target siRNA
transfection did not exert an additive effect on the rate of cell
proliferation compared to the single-target siRNA-transfected
cells (data not shown); thus, we speculate on the possible
redundancy of the proliferative signaling pathways of these
proteins. We then sought to examine the effects of FABP5 and

HMGA1 transcriptional KD on the migration of IMR-32 cells,
since L1-CAM (25) and MYCN (26,27) have been previously
reported to affect neuroblastoma cell migration. Using the
‘wound healing’ scratch assay (Fig. 6C) we observed a significant decrease in the migratory capacity of the IMR-32 cells
subjected to FABP5 or HMGA1 transcriptional KD at 24 h
after ‘wound induction’ (Fig. 6D).
Transcriptional KD of FABP5 and MYCN induces the early
apoptosis of IMR-32 cells. Lastly we wished to determine
whether the transcriptional KD of the tumorigenic proteins
would affect the rate of apoptosis of IMR-32 cells. The late
apoptotic rate was not observed to differ significantly between
the controls and siRNA-transfected cells of any target at 48 h
following transcriptional KD (Fig. 7A). However, early apoptosis was significantly higher in the cells subjected to FABP5
and MYCN transcriptional siRNA KD at 48 h, as determined
by Annexin V/PI staining and FACS analysis (Fig. 7B). This
was confirmed by immunofluorescence staining of the cells
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Figure 6. Transcriptional knockdown of tumorigenic proteins inhibits the proliferation and migration of IMR-32 cells. (A) Transient siRNA transfection and
knockdown of MYCN proto-oncogene, bHLH transcription factor (MYCN), L1-cell adhesion molecule (L1-CAM), high mobility group protein A1 (HMGA1)
and fatty-acid binding protein 5 (FABP5) protein expression led to a significant decrease in IMR-32 cell proliferation from 48-96 h compared to the controls,
as determined using a WST-1 cell proliferation assay. (B) Double-siRNA targeted knockdown (MYCN + L1-CAM, MYCN + HMGA1, MYCN + FABP5,
L1-CAM + HMGA1, L1-CAM + FABP5 and HMGA1 + FABP5) also led to significant decrease in the IMR-32 cellular proliferation rate from 48-96 h
compared to the controls. (C) Representative images of ‘wound closure’ illustrate a reduction in the migratory capacity of the IMR-32 cells subjected to FABP5
and HMGA1 siRNA knockdown. (D) The average area of ‘wound closure’ in multiple random fields, measured using AxioVision Systems software, revealed a
statistically significant decrease in IMR-32 cell migration compared to the controls. Experiments were run in triplicate and repeated >3 times. Results represent
the means ± SEM; *P<0.05.

with Annexin V and PI (Fig. 7C). Perhaps a difference in the
rate of late apoptosis would be observed had we conducted the
apoptosis assay at 72 or 96 h post-transcriptional KD.
Discussion
Neuroblastoma is a devastating childhood cancer with a
dismal prognosis if presented in the high-risk group at diagnosis. IMR-32 is a MYCN-amplified, highly malignant human
neuroblastoma cell line. On the contrary, SK-N-SH, while a
metastatic human neuroblastoma cell line derived from an
epithelial origin (28), is non-MYCN-amplified (29), and hence,
is considered less invasive than the IMR-32 cells and a good
cell line to use in comparison to IMR-32. In addition to the
well-established pathways known to affiliate with MYCN in
tumorigenic processes, we sought to discover whether other
tumorigenic proteins and/or pathways are also 'accomplices' of
the main ‘culprit’ MYCN, in its pursuit of cancerous-progression, malignancy, anti-apoptosis and resistance to treatment in
high-risk neuroblastoma.
Our preliminary analysis of the proteomic signatures in the MYCN-amplified IMR-32 compared to the

non-MYCN-amplified SK-N-SH cells revealed some noteworthy, upregulated tumorigenic proteins in the IMR-32
compared to the SK-N-SH cells. Enrichr mapped these proteins
to highly cancerous pathways, including leptin signaling,
AGE/RAGE signaling, AMPK signaling, Notch, SREBP and
Rac1/Pak1/p38/MMP-2 signaling pathways, among others.
The leptin signaling pathway is highly affiliated with cancer
migration and invasion (30), whereas SREBP, AGE/RAGE,
Notch, Rac and AMPK have all been implicated in the
tumorigenesis of various nervous system cancers, as well as
other solid tumors (19-24). IMR-32 cells represent a highly
malignant, invasive, treatment-resistant form of neuroblastoma
and the identification of these activated pathways within them
has shed some light on the understanding of their malignant
mechanisms.
Of the SILAC identified upregulated proteins, we selected
to verify with western blot analysis, the protein expression of
several that mapped to more than one activated tumorigenic
pathways including, L1-CAM (mapped to upstream regulators
APP and HIF-1α), HMGA1 (mapped to activated upstream
regulators MYC, APP, E2F1, MYCN and SP1), FABP5 (mapped
to activated upstream regulators MYC, SREBF2, SREBF1 and
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Figure 7. Transcriptional knockdown of MYCN proto-oncogene, bHLH transcription factor (MYCN) and fatty-acid binding protein 5 (FABP5) induces cellular
apoptosis of IMR-32 cells. (A) The rate of late cellular apoptosis between MYCN, L1-cell adhesion molecule (L1-CAM), high mobility group protein A1 (HMGA1)
and FABP5 siRNA-transfected and control IMR-32 cells did not differ significantly at 48 h post-transfection as determined using an Annexin V/propidium iodide
(PI) cell apoptosis assay and flow cytometry analysis. (B) The rate of early apoptosis in MYCN and FABP5 siRNA-transfected IMR-32 cells was significantly
higher compared to controls (~27 and ~29% compared to ~17%, respectively) at 48 h post‑transfection. (C) Fluorescence microscopy images of MYCN and FABP5
siRNA-transfected cells stained with Annexin V (red) and PI (green) at 48 h post-transfection. Experiments were run in triplicates and repeated >3 times. Results
represent the mean ± SEM.

KITLG) and survivin or BIRC5 (mapped to activated upstream
regulators IL3, MYCN and MYC) to determine their interaction with MYCN in the IMR-32 cells. As shown in Table V,
there is intriguing overlap between these upstream regulators
in highly tumorigenic pathways including, pathways in cancer,
transcriptional misregulation in cancer, PI3K/AKT, Ras, Rap1,
TGF-β, HIF-1α, Wnt, insulin and mTOR signaling pathways.
The mTOR pathway, one of the most potent signaling pathways involved in cellular proliferation and protein synthesis, is
highly activated in MYCN-amplified cell lines (31). Moreover,
when MYCN-amplified IMR-32 cells are treated with
SU11657 (SUGEN), a selective multi-targeted tyrosine kinase
inhibitor with antitumor and anti-angiogenic activity, their
growth is significantly inhibited (32).
L1-CAM is a neural cell adhesion molecule L1 found to be
expressed in numerous tumors, such as neuroblastomas (25),
glioblastomas, melanomas, lymphomas, as well as breast,
colon, small cell lung carcinomas and gastrointestinal stromal
tumors (33,34). L1-CAM plays a significant role in tumor
progression and metastatic behavior (35), and the expression profile analysis in multiple human tumors has identified
L1-CAM as a molecular marker for differential diagnosis and
targeted therapy (36). Of note, various studies have recently

implicated L1-CAM in cancer stem-cell maintenance and
propagation (37), the activation of DNA damage checkpoint
response that confers resistant to radiation therapy (38) and
cancer cell migration and malignancy (39) in glioblastoma and
neuroblastoma (40). Moreover, the strong interactions between
L1-CAM and EGFR, RANBP9 and NCAM1 (which affiliates
with TGF-β) (41) and NRP1 (Fig. 3), may enhance IMR-32 cell
invasion and metastasis via an angiogenesis-driven, migratory
mechanism.
HMGA1 belongs to a large family of non-histone
DNA-binding factors that play important architectural functions in the organization of active chromatin (42). In addition
to its role in physiologic processes, a deregulated HMGA1
expression is described in most tumors of epithelial and mesenchymal origin, and is considered a hallmark of cancer (43).
Particularly, higher levels of HMGA1 expression are associated
with more malignant and metastatic phenotypes in epithelial
cancers (44,45). Furthermore, HMGA1 regulation may be
controlled by MYCN, which upregulates HMGA1 expression in
neuroblastoma cells and in neuroblastoma-like tumors arising
in MYCN transgenic mice. Moreover, HMGA1 has been shown
to be a direct MYCN transcriptional target, suggesting that
HMGA1 is a biologically relevant MYCN target gene (46).
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Table VI. Common tumorigenic pathways that MYC and our validated targets (BIRC5, HMGA1 and MYCN) mapped to.
			False
Pathway
Pathway
Observed discovery
ID no.
description
gene count
rate
GO.0051301 Cell division
6
0.000118
				
GO.0007067 Mitotic nuclear division
5
0.000834
GO.0007052 Mitotic spindle organization
3
0.0017
GO.0007059 Chromosome segregation
4
0.0017
GO.0043146 Spindle stabilization
2
0.00178
GO.0051225 Spindle assembly
3
0.00178
GO.0051302 Regulation of cell division
4
0.00382
GO.0007264 Small GTPase-mediated
5
0.00405
signal transduction
GO.0000910 Cytokinesis
3
0.00568
GO.0031145 Anaphase-promoting
3
0.00568
complex-dependent
proteasomal ubiquitin-dependent
protein catabolic process
GO.0010941 Regulation of cell death
6
0.00604
				
GO.0006468 Protein phosphorylation
5
0.00685
GO.0018105 Peptidyl-serine phosphorylation
3
0.00685
GO.0034501 Protein localization to kinetochore
2
0.00685
GO.0035404 Histone-serine phosphorylation
2
0.00685
GO.0043066 Negative regulation of apoptotic process
5
0.00685
GO.0051276 Chromosome organization
5
0.00736
GO.0006996 Organelle organization
7
0.00837
				
GO.0051781 Positive regulation of cell division
3
0.0103
GO.0035556 Intracellular signal transduction
6
0.0104
				
GO.0000086 G2/M transition of mitotic cell cycle
3
0.0122
GO.0022402 Cell cycle process
5
0.0122
GO.1902589 Single-organism organelle organization
6
0.0131
				
GO.0033043 Regulation of organelle organization
5
0.0134
GO.0090307 Mitotic spindle assembly
2
0.0136
GO.0016568 Chromatin modification
4
0.0151
GO.0007049 Cell cycle
5
0.026
GO.0000075 Cell cycle checkpoint
3
0.0275
GO.0002053 Positive regulation of mesenchymal
2
0.0275
cell proliferation
GO.0007098 Centrosome cycle
2
0.0275
GO.0090068 Positive regulation of cell cycle process
3
0.0338
GO.0031577 Spindle checkpoint
2
0.0342
GO.1903047 Mitotic cell cycle process
4
0.0372
GO.0030162 Regulation of proteolysis
4
0.0399
GO.0045840 Positive regulation of mitotic
2
0.0412
nuclear division
GO.0051303 Establishment of
2
0.0434
chromosome localization
GO.0010639 Negative regulation of
3
0.0455
organelle organization

Matching proteins in
your network (labels)
AURKA, AURKB, BIRC5, CDCA8,
CDK1, INCENP
AURKB, BIRC5, CDCA8, CDK1, INCENP
AURKA, AURKB, BIRC5
AURKB, BIRC5, CDCA8, INCENP
AURKA, AURKB
AURKA, AURKB, BIRC5
AURKA, AURKB, BIRC5, MYC
AURKB, BIRC5, CDCA8, CDK1, INCENP
AURKB, BIRC5, INCENP
AURKA, AURKB, CDK1

AURKA, AURKB, BIRC5, CDK1,
MYC, MYCN
AURKA, AURKB, BIRC5, CDK1, MYC
AURKA, AURKB, CDK1
AURKB, CDK1
AURKA, AURKB
AURKA, AURKB, BIRC5, CDK1, MYC
AURKA, AURKB, CDCA8, HMGA1, MYC
AURKB, BIRC5, CDCA8, CDK1, HMGA1,
INCENP, MYC
AURKA, AURKB, BIRC5
AURKB, BIRC5, CDCA8, CDK1,
INCENP, MYC
AURKA, BIRC5, CDK1
AURKB, BIRC5, CDCA8, INCENP, MYC
AURKB, BIRC5, CDCA8, CDK1,
HMGA1, INCENP
AURKA, AURKB, BIRC5, HMGA1, MYC
AURKB, BIRC5
AURKA, AURKB, HMGA1, MYC
AURKB, BIRC5, CDCA8, INCENP, MYC
AURKB, BIRC5, CDK1
MYC, MYCN
AURKA, CDK1
AURKA, AURKB, BIRC5
AURKB, BIRC5
AURKB, BIRC5, CDCA8, INCENP
AURKA, BIRC5, CDK1, MYC
AURKA, BIRC5
BIRC5, CDCA8
AURKA, AURKB, HMGA1

As indicated, there was a strong interaction between BIRC5, HMGA1, MYC, MYCN and AURKA/B, CDK1 and CDCA8, all of which are
highly affiliated with processes that drive cellular mitosis.
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STRING protein network analysis mapped HMGA1 to
MYCN, SP1, E2F1 and SREBP1 [a transcription factor with
an important role in lipid metabolism, previously found to
be highly activated in malignancies (47)], SREBP-cleavageactivating protein [SCAP which plays a role in trafficking
SREBP1 from the ER to the Golgi apparatus and recently
found to play a role in tumorigenesis (48)], insulin-like growth
factor receptor 1 [IGF1R or INSR, a known driver of HIF-2α
transcription via PI3K signaling (49)] and the gene KITLG
[which codes for the ligand of the tyrosine-kinase receptor
c-KIT, STAT1 and STAT4 and implicated in the susceptibility of germ cell tumors such as testicular cancer (50,51)].
Furthermore, when we examined the networks linking
only HMGA1, BIRC5 and MYCN, we identified very strong
interactions with the highly tumorigenic AURKA/B, CDK1,
CDCA8 (52) and INCENP (53). As strong cell proliferation
players, we speculate that the IMR-32 cells overexpressing
HMGA1 and MYCN have an enhanced mitotic and cell division
capacity that favors tumor cell proliferation and the evasion of
apoptosis. With HMGA1 being a common player in the abovementioned tumorigenic pathways, including HIF-1α, SREBP1,
KITLG, AURKA/B, CDK1 and CDCA8, it is no surprise that
MYCN-amplified IMR-32 cells or high-risk, MYCN-amplified
neuroblastomas are highly malignant cancers.
FABP5 binds with a strong affinity to medium and long
chain fatty acids, and translocates them into the nucleus
where they stimulate their nuclear receptor PPARγ, which
in turn stimulates other targets that lead to cancer expansion and progression by enhanced angiogenesis and reduced
apoptosis (54). Based on previous studies that have shown
FABP5 upregulation in various tumors, its association with
cancer malignancy and invasiveness (55) and the demonstrated antitumor activity of the FABP5 chemical inhibitor
SBFI26 (56), we decided to evaluate its role in the IMR-32
neuroblastoma cells. We were particularly interested in FABP5
as there are limited studies exploring its role in the aggressive,
MYCN‑amplified neuroblastoma cells. We were very intrigued
by the observation that FABP5 mapped to the highly tumorigenic MYC, SREBF1, SREBF2 and KITLG pathways further
explaining the malignant nature of the IMR-32 cells.
Survivin or BIRC5 expression is strongly upregulated
in aggressive, high-risk neuroblastoma compared to normal
tissues, adult malignancies and non-malignant fetal adrenal
neuroblasts (57). This upregulation correlates with an unfavorable prognosis in patients with neuroblastoma (58,59). BIRC5
is a key regulator of mitosis and programmed cell death or
apoptosis (60) and the smallest member of the family of
inhibitor-of-apoptosis proteins (IAPs) (61,62). Thus, it is an
ideal target for killing tumor cells specifically, while sparing
healthy normal cells. We found BIRC5 to be highly affiliated
with HMGA1, MYC and MYCN in the AURKA/B pathways,
which may be critical interactions that fuel IMR-32 cell proliferation and malignancy. In addition, STRING network analysis
identified interactions between BIRC5 and IL3 [a stimulator
of STATs and AKT pathways (63)] and HIF-1α [an angiogenic driver in oxygen-deprived solid tumors (64) previously
reported to protect neuroblastoma cells from hypoxia-induced
apoptosis (63)]. The common denominator here is MYC,
our validated targets affiliated either directly or indirectly
(for example via MYCN) with MYC. Moreover, the intricate

network between MYC, MYCN, AURKA/B and NCAM1, and
our targets L1-CAM, HMGA1, BIRC5 and FABP5 links them
to highly proliferative, angiogenic and metastatic tumorigenic
pathways.
The transcriptional KD of all our proteins significantly
inhibited the proliferation of IMR-32 cells and FABP5
and MYCN KD inhibited early apoptosis, while FABP5 or
HMGA1 KD inhibited cellular migration. The double-target
transcriptional KD did not yield an additive effect on cell
proliferation compared to single-target KD, implying that these
proteins may signal through redundant proliferative pathways.
In fact, HMGA1 and MYCN have been found to co-interact
and HMGA1 was identified as a direct MYCN transcriptional
regulator (46), which would explain the lack of an additive
effect with combined, siRNA transcriptional KD of both
targets, compared to single-target KD in our cells. Others have
demonstrated the interplay between L1-CAM and EGFR in
promoting cancer proliferation via ERK activation (65). ERK
is a protein downstream of EGFR, platelet-derived growth
factor receptor (PDGFR) and vascular endothelial growth
factor (VEGFR) signaling, which are receptor tyrosine kinases
that our validated proteins may signal through. For example,
the FABP5-PPARγ-VEGF signaling transduction axis has
been reported to be the pivotal tumorigenic pathway in prostate cancer progression and malignancy (54). Furthermore,
L1-CAM (66), HMGA1 (67) and MYCN (68), have all been
reported to inhibit p53, thereby affecting cellular proliferation;
in addition, L1-CAM (69), FABP5 (54) and MYCN all signal
through the mTOR pathway via PI3K/AKT activation, and this
may therefor explain the lack of an additive effect between
single-target versus double-target KD on cell proliferation.
The fact that FABP5 and MYCN KD were able to induce
early apoptosis of our IMR-32 cells at 48 h post-transfection
implies that these proteins are crucial for cellular survival and
thus early apoptotic rates were observed 48 h following their
transcriptional KD. In support of our findings, Kawaguchi et al
demonstrated the interaction of FABP5 with SP-1 and c-MYC
(both determined by IPA to be upregulated in the IMR-32
compared to SK-N-SH cells) to enhance cellular proliferation
in cancer cells and the anti-proliferative effects of FABP5,
SP1 or c-MYC silencing in prostate cancer cells (70). We
have previously demonstrated the interplay between MYCN
and L1-CAM in conferring the radioresistance of IMR-32
cells (25) and L1-CAM has been previously reported to sustain
ERK, FAK and PAK phosphorylation in apoptosis-resistant
ovarian cancers, whereas its transcriptional KD sensitized
ovarian carcinoma cells to apoptotic stimuli (71). We speculate that the interplay between L1-CAM, FABP5 and MYCN
in this aggressive neuroblastoma cell line may be driving
its malignant, apoptosis-resistant behavior. Of note, a recent
study demonstrated the efficacy and safety of using the CE7
monoclonal antibody to target L1-CAM in a (CAR)-redirected
T-cell mediated immuno-therapy for children with neuroblastoma (72), which has shown promise in providing both in vitro
and in vivo antitumor activity in primary, metastatic and
recurrent neuroblastoma.
Our proteins validated by western blot analysis mapped to
highly tumorigenic, activated upstream regulators which may
help explain the aggressive nature of these malignant MYCNamplified cells. Seeing all these tumorigenic players highly
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expressed in the IMR-32 neuroblastoma cells and of particular
interest, their mapping to the activated upstream regulator,
MYCN is quite intriguing and highlights the possible mechanisms responsible for the aggressive, malignant nature of these
cells. For instance, ISNR, SP1, SREBF1, IL3 and HIF-1α,
which enhance tumor cell survival under stress-hypoxic
conditions that favor proliferative processes and angiogenesis,
may function as strong ‘accomplices’ of the main ‘culprit’,
MYCN, in driving the malignant, tumorigenic behaviors of
the IMR-32 cell line. In addition, AURKA/B with its strong
interaction with HMGA1, BIRC5, MYC and MYCN, as well as
the strong interaction between L1-CAM and the migratory and
angiogenic players, including EGFR, RANBP1, NCAM1 and
NRP1, may further be fueling the malignant propensity of the
MYCN-amplified IMR-32 cells and the high-risk childhood
neuroblastomas.
In conclusion, neuroblastoma that presents at diagnosis
with high-risk disease is extremely difficult to cure and longterm survival is rarely documented. It is of utmost importance
to target the highly malignant, treatment evasive form of
this disease with multi-modality therapeutic approaches.
As demonstrated in the present study, the MYCN-amplified
IMR-32 cells express highly tumorigenic proteins that belong
to pathways that govern metastasis, invasion and migration of
cancer cells; cancer stem cell propagation and maintenance;
cancer angiogenesis, proliferation and evasion of apoptosis. In
addition, our observation that the transcriptional KD of one
target simultaneously downregulated another tumorigenic
target indicates that an important network of interplay exists
between highly tumorigenic proteins in these malignant
cancer cells.
To the best of our knowledge, we are the first to illustrate
the molecular crosstalk between these tumorigenic proteins
and their affiliation with highly tumorigenic pathways in the
MYCN-amplified IMR-32 neuroblastoma cells. Future studies
are warranted to explore these interactions and to elucidate the
exact mechanisms of this crosstalk, both at the cellular level
and in pre-clinical models. Multi-modality targeted therapy
against several non-redundant tumorigenic pathways may
cripple this devastating disease and hinder malignant recurrence that almost always resists therapy, leading to mortality
in affected children.
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